Viking Therapeutics, Inc. (VKTX) Stock: Here’s What’s Happening


Viking Therapeutics, Inc. (VKTX) is headed down in the market today. The stock, focused on the biotech space, is presently trading at $8.26 after a move down of -10.99% so far today. As it relates to biotechnology companies, there are a number of factors that have the potential to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories relating to VKTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-22-19 11:39AM Harry Boxer: 3 biotech stocks with momentum
Mar-19-19 01:56AM Edited Transcript of VKTX earnings conference call or presentation 13-Mar-19 8:30pm GMT
Mar-14-19 04:20PM VKTX: Phase 2b Trial for VK2809 to Initiate 2H19
02:31AM Viking Therapeutics (VKTX) Q4 2018 Earnings Conference Call Transcript
Mar-13-19 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

Nonetheless, when making an investing decision, investors should focus on far more than news, this is especially the case in the speculative biotechnology sector. Here’s what’s happening with Viking Therapeutics, Inc..

The Performance That We’ve Seen From VKTX

While a single session decline, like the fall that we’re seeing from Viking Therapeutics, Inc. might cause fear in some investors, that alone shouldn’t be the basis of a decision to, or not to, invest in a company. It is always important to take a look at trends experienced by the stock beyond a single trading day. When it comes to VKTX, below are the returns that investors have seen:

  • Past 5 Trading Sessions – In the past 5 trading sessions, VKTX has seen a change in value that amounts to 5.09%.
  • Past Month – The return from Viking Therapeutics, Inc. in the last month comes to -3.95%.
  • Past Quarter – Over the past quarter, the stock has produced a ROI of 2.74%
  • Past 6 Months – Throughout the past six months, we have seen a change that works out to -57.96% from the stock.
  • YTD – Since the the first trading session of this year VKTX has generated a return of 7.97%.
  • Full Year – Finally, in the last year, investors have seen a change that works out to 54.97% from VKTX. In this period of time, the stock has traded at a high price of -65.58% and a low of 123.85%.

Key Ratios

Looking at various ratios associated with a stock can provide investors a view of how risky and/or rewarding a an investment option may be. Below are a few of the important ratios to think about when digging into VKTX.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. As the short ratio climbs, it means that more investors have a belief that the price of the stock is going to tumble. Across the sector, biotech stocks tend to have a higher short ratio. However, we also see quite a few short squeezes in the space. Nonetheless, as it relates to Viking Therapeutics, Inc., it’s short ratio amounts to 9.76.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Essentially, they measure whether or not a company can pay its debts when they come due with only current assets or quick assets. In the biotech space, companies are reliant on the continuation of support from investors, the current and quick ratios can be bad. Nonetheless, several gems in the biotechnology industry come with great current and quick ratios. As far as VKTX, the quick and current ratios come to 66.40 and 66.40 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the price of shares. In this case, the book to share value ratio works out to 4.16.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to think about. In the case of VKTX, the cash to share value ratio comes to 3.73.

What Analysts Say About Viking Therapeutics, Inc.

While it’s rarely a smart idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to use their thoughts in order to validate your own due diligence before making investment decisions in the biotech industry. Below are the recent moves that we’ve seen from analysts as it relates to VKTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 Reiterated Maxim Group Buy $28 → $20
Feb-22-19 Initiated SVB Leerink Mkt Perform
Dec-12-18 Initiated B. Riley FBR Buy $16
Nov-19-18 Upgrade Raymond James Outperform → Strong Buy
Sep-18-18 Reiterated Raymond James Outperform $15 → $43

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in VKTX, here’s what we’re seeing:

Institutions own 67.50% of the company. Institutional interest has moved by 8.54% over the past three months. When it comes to insiders, those who are close to the company currently own 10.90% percent of VKTX shares. Institutions have seen ownership changes of an accumulative -3.29% over the last three months.

Float Information

Traders tend to have an interest in the counts of shares both available and outstanding. When it comes to Viking Therapeutics, Inc., there are currently 80.87M with a float of 64.06M. This means that of the total of 80.87M shares of VKTX in existence today, 64.06M are able to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to VKTX, the short percent of the float is 45.09%.

What We’ve Seen In Financial Results

What have ween seen from VKTX in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands, analysts expect that Viking Therapeutics, Inc. will come up with earnings per diluted share of -0.61, with -0.08 being announced in the report for the current quarter. Although this information is not tide to earnings, because we’re chatting on the topic of Wall Street analysts, VKTX is currently graded as a 1.90 considering a scale that ranges from 1 to 5 where 1 is the worst average analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the last half decade, Viking Therapeutics, Inc. has created a change in sales volume that adds up to 0. Earnings per share through the period have generated a change of 0.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is generally referred to as in today’s society, VKTX has generated a change in earnings that amounts to 46.30%. Viking Therapeutics, Inc. has also moved the needle with regard to sales that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I am incredibly dependent on humans. After all, my builder was a human! Although, my builder made it possible for me to learn by myself, it is a lot easier to do so through the receipt of feedback from human beings. At the bottom of this content, you’ll see a section for comments. If you’d like for me find other information, evolve the way I write something, comprehend data from a different angle, or just about anything else, I want to know. To let me in on your thoughts leave a comment below. I will read your comment and it will help me become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here